F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.
about
F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profileMutant mouse models: genotype-phenotype relationships to negative symptoms in schizophreniaRealistic expectations of prepulse inhibition in translational models for schizophrenia research.Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophreniaComparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research.The phytocannabinoid, Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to produce antipsychotic effects.Optimisation of anti-psychotic therapeutics: a balancing act?Increased impulsivity and disrupted attention induced by repeated phencyclidine are not attenuated by chronic quetiapine treatment.The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment.Leading compounds for the validation of animal models of psychopathology.COMT and 5-HT1A-receptor genotypes potentially affect executive functions improvement after cognitive remediation in schizophrenia.Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour.The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats.
P2860
Q24564963-5EBAAA51-0343-4E0A-9FB8-84E61DB49628Q24564964-576C75F1-42E4-4C48-9EDF-4E1BDFC412F3Q24632939-873DD532-DA25-4344-8AE7-833637C2A5C4Q24645703-E1BFC61A-0B23-410C-B75F-CFBD98997B27Q30489404-86E7B53A-2175-4290-9927-1BD1BDF9C835Q33976994-3358D990-4568-400E-B1DF-1A2F472D719BQ34169978-51C4D776-E92E-4570-8A17-DE474F3E5B77Q34350194-085E58FB-45E6-4375-9B3F-B3AF9ADEDA38Q35111468-299C3DB0-061D-4F1B-BB15-5A2B2E19A8A8Q36052751-52D40DA4-9F3B-4A9A-B154-D986B1347828Q37354597-17F8A380-69AF-459B-A2C9-FF683EAD7998Q37826638-0737607B-A1A0-4616-8CFB-C20B8AEC74A8Q38128733-020F8FB5-9802-406B-9290-6928E898373EQ43170052-C9C1AAF4-0DD6-499C-BA5F-EC6F60364B66Q46565107-C2ED35D0-32B2-4531-B130-0474D97919E1Q50974329-1FFFD394-5623-434E-8CCF-506425C9644D
P2860
F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
F15063, a compound with D2/D3 ...... gnition and negative symptoms.
@ast
F15063, a compound with D2/D3 ...... gnition and negative symptoms.
@en
type
label
F15063, a compound with D2/D3 ...... gnition and negative symptoms.
@ast
F15063, a compound with D2/D3 ...... gnition and negative symptoms.
@en
prefLabel
F15063, a compound with D2/D3 ...... gnition and negative symptoms.
@ast
F15063, a compound with D2/D3 ...... gnition and negative symptoms.
@en
P2093
P2860
P356
P1476
F15063, a compound with D2/D3 ...... ognition and negative symptoms
@en
P2093
A L Auclair
F Colpaert
L Bruins Slot
M S Kleven
R Depoortère
P2860
P304
P356
10.1038/SJ.BJP.0707160
P407
P577
2007-03-20T00:00:00Z